Boehringer Ingelheim Animal Health has decided to remain focused on freshly mixed Porcine Circovirus type 2 (PCV2)/ Mycoplasma hyopneumoniae (M.hyo) vaccines and not follow the development of a PCV2/M.hyo ready-to-use (RTU) vaccine combination. As a consequence of this decision, the company has discontinued its PCV2/M.hyo RTU research program.
Boehringer Ingelheim’s research programme on swine vaccines against PCV2/M.hyo has revealed that the highest protection was observed for its vaccines when freshly mixed.
An RTU design does not meet its standards for efficacy and safety, the company says, and Boehringer Ingelheim will continue to invest in the FLEX concept of freshly mixed vaccines. Although initial data was promising, it became evident over time that in this case, the RTU design does not meet the high standards of efficacy and safety for which Boehringer Ingelheim’s FLEXcombo® platform is known.
In essence, Boehringer Ingelheim's PCV2/M.hyo research programme revealed that the highest protection against both pathogens was observed for its vaccines when freshly mixed and applied in accordance with manufacturer recommendations. The FLEXcombo® platform of mixable vaccines protects pigs against PCV2 and M.hyo with a single dose.
In 2013, Boehringer Ingelheim introduced the MycoFLEX® headspace bottle, a simple and practical way to mix the two pig vaccines Ingelvac CircoFLEX® and Ingelvac MycoFLEX for their simultaneous application. The same trusted concept is used for 3FLEX®, the mix of Ingelvac CircoFLEX, Ingelvac MycoFLEX and Ingelvac PRRS MLV®, which is presently licensed in North America and several Asian countries. Ingelvac CircoFLEX is established globally as market leader for PCV2-vaccination while Ingelvac MycoFLEX is the market leader in a number of key swine markets. Boehringer Ingelheim is dedicated to continue its research efforts on these core antigens.